1. Home
  2. PRT vs LPCN Comparison

PRT vs LPCN Comparison

Compare PRT & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PermRock Royalty Trust Trust Units

PRT

PermRock Royalty Trust Trust Units

SELL

Current Price

$1.42

Market Cap

18.0M

Sector

Energy

ML Signal

SELL

Logo Lipocine Inc.

LPCN

Lipocine Inc.

SELL

Current Price

$1.67

Market Cap

18.7M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PRT
LPCN
Founded
2017
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.0M
18.7M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
PRT
LPCN
Price
$1.42
$1.67
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $5.00
AVG Volume (30 Days)
49.8K
★ 202.5K
Earning Date
11-27-2026
11-05-2026
Dividend Yield
★ 14.03%
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $1,976,677.00
Revenue This Year
$654.36
N/A
Revenue Next Year
N/A
$18.02
P/E Ratio
$7.78
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.20
$1.36
52 Week High
$3.95
$12.37

Technical Indicators

Market Signals
Indicator
PRT
LPCN
Relative Strength Index (RSI) 35.81 51.88
Support Level $1.20 $1.36
Resistance Level $2.32 $2.30
Average True Range (ATR) 0.07 0.12
MACD 0.02 0.04
Stochastic Oscillator 66.67 82.05

Price Performance

Historical Comparison
PRT
LPCN

About PRT PermRock Royalty Trust Trust Units

PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.

About LPCN Lipocine Inc.

Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Share on Social Networks: